[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,227,806
  • Shares Outstanding, K 23,056
  • Annual Sales, $ 958,400 K
  • Annual Income, $ -288,280 K
  • EBIT $ -314 M
  • EBITDA $ -307 M
  • 60-Month Beta -1.07
  • Price/Sales 11.86
  • Price/Cash Flow N/A
  • Price/Book 20.90

Options Overview Details

View History
  • Implied Volatility 47.74% (+1.63%)
  • Historical Volatility 46.94%
  • IV Percentile 19%
  • IV Rank 30.11%
  • IV High 73.99% on 11/03/25
  • IV Low 36.43% on 05/06/26
  • Expected Move (DTE 12) 14.20 (2.91%)
  • Put/Call Vol Ratio 0.82
  • Today's Volume 62
  • Volume Avg (30-Day) 608
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 19,821
  • Open Int (30-Day) 19,455
  • Expected Range 472.79 to 501.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.04
  • Number of Estimates 6
  • High Estimate $-0.75
  • Low Estimate $-3.01
  • Prior Year $-1.90
  • Growth Rate Est. (year over year) -7.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
445.20 +9.38%
on 06/03/26
559.00 -12.88%
on 05/06/26
-15.49 (-3.08%)
since 05/05/26
3-Month
418.72 +16.30%
on 03/09/26
572.20 -14.89%
on 03/26/26
+47.64 (+10.84%)
since 03/05/26
52-Week
275.00 +77.08%
on 06/18/25
615.00 -20.82%
on 12/24/25
+212.88 (+77.67%)
since 06/05/25

Most Recent Stories

More News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 486.98 (-1.19%)
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47 th Annual Global Goldman Sachs Health Care...

MDGL : 486.98 (-1.19%)
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Growing body of clinical and real-world evidence supports the role of Rezdiffra ® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles...

MDGL : 486.98 (-1.19%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 486.98 (-1.19%)
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year...

MDGL : 486.98 (-1.19%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 486.98 (-1.19%)
Madrigal: Q1 Earnings Snapshot

Madrigal: Q1 Earnings Snapshot

MDGL : 486.98 (-1.19%)
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% As of  March 31, 2026, more than 42,250 patients on Rezdiffra, up...

MDGL : 486.98 (-1.19%)
Madrigal's First Full Quarter of Rezdiffra Sales With Nowhere Left to Hide

Barchart Research What to Expect from MDGL Earnings MDGL Generated May 5, 2026 Current Price $502.47 EPS Estimate $$-3.61 Consensus Rating Strong Buy Average Move 10.52% Madrigal's First Full Quarter of...

MDGL : 486.98 (-1.19%)
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England...

ARWR : 73.09 (-2.75%)
MDGL : 486.98 (-1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 507.80
2nd Resistance Point 501.49
1st Resistance Point 494.24
Last Price 486.98
1st Support Level 480.67
2nd Support Level 474.36
3rd Support Level 467.11

See More

52-Week High 615.00
Last Price 486.98
Fibonacci 61.8% 485.12
Fibonacci 50% 445.00
Fibonacci 38.2% 404.88
52-Week Low 275.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.